Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026Initiation of Phase 3 study of ...

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +1.12% and -57.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101 Patient with high-risk, TP53-mutated MDS ...

Ratings for TScan Therapeutics (NASDAQ:TCRX) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table ...

As of Friday, April 17, TScan Therapeutics, Inc.’s TCRX share price has surged by 7.40%, which has investors questioning if this is right time to sell.

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients ...

Researchers from Tscan Therapeutics Inc. presented preclinical data for TSC-200-A0201, a naturally occurring HPV16 E7-specific T-cell receptor (TCR) T-cell therapy discovered using Tscan’s proprietary ...

All TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with ...

In the preceding three months, 6 analysts have released ratings for TScan Therapeutics (NASDAQ:TCRX), presenting a wide array of perspectives from bullish to bearish. The following table summarizes ...

WALTHAM, Mass.--(BUSINESS WIRE)--TScan Therapeutics, a biopharmaceutical company focused on the development of T cell receptor (TCR) therapies which reprogram a patient’s own T cells to recognize ...

A dose bottle of the medication is in the medical tech's hand As of March 19, 2026, analysts maintain a strong sentiment regarding TScan Therapeutics, Inc. (TCRX). With over 80% of analysts holding a ...

Amgen and TScan Therapeutics announced a collaboration Tuesday morning to pursue novel targets in Crohn’s disease. As part of the deal, Amgen will pay TScan $30 million up front, with the potential ...